

DAFTAR PUSTAKA

1. Dinda Aprilistya Puri, Murti S, Riasiti Y. Insidensi dan Karakteristik Karsinoma Hepatoseluler di RSUD Abdul Wahab Sjahranie Samarinda. *J Sains dan Kesehatan* [Online] 2021;3(2):158–64. Dari : <https://repository.unmul.ac.id/handle/123456789/27781> [4 Maret 2024].
2. Syafinatunnajah G, Rizkia A, Widyantari DD, Putri NPWPN, Budyono C. Hepatocellular Carcinoma: Risk Factors and Diagnosis. *J Biol Trop* [Online] 2023;23(1):236–44. Dari : <https://jurnalfkp.unram.ac.id/index.php/JBT/article/view/5750/3439> [4Maret 2024].
3. Huang DQ, Singal AG, Kono Y, Tan DJH, El-Serag HB, Loomba R. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. *Cell Metab* [Online] 2022;34(7):969–77. Dari : <https://pubmed.ncbi.nlm.nih.gov/35793659/> [4 Maret 2024].
4. Runggay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. *J Hepatol* [Online] 2022;77(6):1598–606. Dari : <https://doi.org/10.1016/j.jhep.2022.08.021> [4 Maret 2024].
5. Devarbhavi H, Asrani SK, Arab JP, Narthey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. *J Hepatol* [Online] 2023;79(2):516–37. Dari : <https://pubmed.ncbi.nlm.nih.gov/36990226/> [4 Maret 2024].
6. Rahmawati WD, Sukmaningtyas W. Implementasi Teknik Relaksasi Napas Dalam Pada Pasien Hepatoma Dengan Masalah Gangguan Aman Nyaman. *J Keperawatan Notokusumo* [Online] 2023;11(1):1–10. Dari : <https://jurnal.stikes-notokusumo.ac.id/index.php/jkn/article/view/246/188> [4 Maret 2024].
7. Fadillah MAM, Mashuri M, Triawanti T, Mulyani N, Rosida A. Profil Pasien Karsinoma Hepatoseluler yang Menjalani Terapi Transarterial Chemoembolization (TACE) di RSUD Ulin Banjarmasin Periode 2016-2018. *Homeostasis* [Online] 2022;5(1):19. Dari : <https://doi.org/10.20527/ht.v5i1.5158> [4 Maret 2024].
8. Bachtiar R, Parewangi ML, Akil F, Daud NA, Kusuma SH, Rifai A. Perubahan Paradigma pada Strategi Penanganan Karsinoma Hepatoseluler: Systematic Review. *UMI Med J* [Online] 2022;7(1):59–71. Dari : <https://doi.org/10.33096/umj.v7i1.150> [4 Maret 2024].
9. Katadata.10 Jenis Kanker dengan Kasus Tertinggi Nasional 2020. Katadata: <https://databoks.katadata.co.id/datapublish/2021/06/29/ini-jenis-kanker-yang-paling-banyak-diderita-penduduk-indonesia; 2024>.
10. Tim Laporan RSUP DR M.Djamil. Lembar Tahunan Rumah Sakit Umum Pusat Dr . M . Djamil Padang Tahun 2022. Padang : Tim Laporan RSUP Dr. M. Djamil;2023.
11. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of the hepatocellular carcinoma. *Hepatology* [Online] 2021;1:4–13. Dari : <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577946/> [4 Maret 2024].
12. Feng D, Wang M, Hu J, Li S, Zhao S, Li H, et al. Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma and other liver diseases. *Ann Transl Med* [Online] 2020;8(8):553–553. Dari :

- <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214886/> [31 Maret 2024].
13. Hao XY, Li AQ, Shi H, Guo TK, Shen YF, Deng Y, et al. A novel DNA methylation-based model that effectively predicts prognosis in hepatocellular carcinoma. *Biosci Rep* [Online] 2021;41(3):1–16. Dari : <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955104/> [31 Maret 2024]
 14. National Cancer Institute. Advanced Cancer. National Cancer Inst : <https://www.cancer.gov/about-cancer/advanced-cancer>; 2024.
 15. Wijyaningrum SE, Sitanggang FP, Patriawan P. Laporan Kasus: Transarterial Chemoembolization (Tace) Sebagai Terapi Pilihan Pada Karsinoma Hepatoselular. *J Ilm Kedokt Wijaya Kusuma* [Online] 2020;9(1):49–59. Dari : <http://dx.doi.org/10.30742/jikw.v9i1.732> [4 Maret 2024].
 16. MacKee N. Understanding Liver Cancer. Australia: Cancer Council; 2022.
 17. Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nomor Hk.01.07/Menkes/1355/2022 Tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Karsinoma Sel Hati Pada Dewasa. Jakarta; Kementerian Kesehatan RI.2022.
 18. Liang F, Ma F, Zhong J. Prognostic factors of patients after liver cancer surgery. *Medicine (Baltimore)* [Online] 2021;100(30):1–6. Dari : <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322491/> [4 Maret 2024].
 19. Zhou L, Wang S Bin, Chen SG, Qu Q, Rui JA. Risk factors of recurrence and poor survival in curatively resected hepatocellular carcinoma with microvascular invasion. *Adv Clin Exp Med* [Online] 2020;29(7):887–92. Dari : <https://pubmed.ncbi.nlm.nih.gov/32750753/> [4 Maret 2024].
 20. Zhu Y, Gu LL, Zhang FB, Zheng GQ, Chen T, Jia WD. Long-Term Survival and Risk Factors in Patients with Hepatitis B-Related Hepatocellular Carcinoma: A Real-World Study. *Can J Gastroenterol Hepatol* [Online] 2022;1–9. Dari : <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427325/> [4 Maret 2024].
 21. Zheng Y, Zhang X, Lu J, Liu S, Qian Y. Association between socioeconomic status and survival in patients with hepatocellular carcinoma. *Cancer Med* [Online] 2021;10(20):7347–59. Dari : <https://pubmed.ncbi.nlm.nih.gov/34414679/> [15 Mare 2024].
 22. Sarpel U, Heskell M, Spivack JH, Feferman Y, Ang C. Disparities in Access to Sorafenib in Communities with Low Socioeconomic Status. *HSS Public Access* [Online] 2018;29(3):1123–34. Dari : <https://pubmed.ncbi.nlm.nih.gov/30122687/> [15 Maret 2024].
 23. Cheng HH, Kamarck TW, Gianaros PJ, Roeklein KA, Vanegas Y, Tsung A, et al. Socioeconomic disparities of depressive symptoms and cytokines in hepatocellular carcinoma. *Psychooncology* [Online] 2019;28(8):1624–32. Dari : <https://pubmed.ncbi.nlm.nih.gov/31119824/> [15 Maret 2024].
 24. The American Cancer Society Medical team. About Liver Cancer. American Cancer Society: <https://www.cancer.org/cancer/types/liver-cancer/about/what-is-liver-cancer.html>; 2024.
 25. Cancer Research UK. Types of Liver Cancer. Cancer Research UK: <https://www.moffitt.org/cancers/liver-hepatocellular-cancer/types/>; 2024.
 26. Sergi CM. Liver Cancer. Australia: Exon Publications, Brisbane; 2021.
 27. Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. *Adv Cancer Res* [Online] 2021;149:1–61. Dari : <https://pubmed.ncbi.nlm.nih.gov/33579421/> [6 Maret 2024].

28. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. *Nat Rev Dis Prim* [Online] 2021;7(1). Dari : <https://www.ncbi.nlm.nih.gov/books/NBK559177/> [31 Maret 2024].
29. Michielsen PP, Francque SM, van Dongen JL. Viral hepatitis and hepatocellular carcinoma. *World J Surg Oncol* [Online] 2005;3:1–18. Dari : <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1166580/> [31 Maret 2024].
30. Li H, Guo W min, Xie Q, Sun X, Wang Q. Clinical characteristics and survival analysis of patients with hepatocellular carcinoma after hepatitis B virus turning negative. *Adv Clin Exp Med* [Online] 2022;31(7):731–738. Dari : <https://pubmed.ncbi.nlm.nih.gov/35302303/> [18 Maret 2024].
31. Pinyopornpanish K, Al-yaman W, Dasarathy S, Romero-marrero C, Mccullough A. Hepatocellular Carcinoma in Patients Without Cirrhosis: The Fibrosis Stage Distribution, Characteristics and Survival [Online] 2022;67(6):2677–87. Dari : <https://pubmed.ncbi.nlm.nih.gov/34027591/> [18 Maret 2024].
32. Chen F, Wu Y, Xu H, Song T, Yan S. Impact of marital status on overall survival in patients with early - stage hepatocellular carcinoma. *Sci Rep* [Online] 2022;1–8. Dari : <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675859/> [18 Maret 2024].
33. Massarweh NN, El-Serag HB. Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. *Cancer Control* [Online] 2017;24(3):1–11. Dari : <https://pubmed.ncbi.nlm.nih.gov/28975830/> [6 Maret 2024].
34. Zhou K, Lim T, Dodge JL, Terrault NA. Population attributable risk of modifiable lifestyle factors to hepatocellular carcinoma. the Multiethnic Cohort [Online] 2023;58(1):89–98. Dari : <https://pubmed.ncbi.nlm.nih.gov/37051717/> [4 Maret 2024].
35. Zelber-Sagi S, Noureddin M, Shibolet O. Lifestyle and hepatocellular carcinoma what is the evidence and prevention recommendations. *Cancers (Basel)* [Online] 2022;14(1):1–23. Dari : <https://pubmed.ncbi.nlm.nih.gov/35008267/> [31 Maret 2024].
36. Sun B, Zhang L, Xiang D, Li Q, Ren Y, Cao Y, et al. The Effect of Alcohol Consumption in Unresectable Hepatocellular Carcinoma with Transarterial Chemoembolization. *Genet Res (Camb)* 2022;2022. Dari : <https://pubmed.ncbi.nlm.nih.gov/36618073/> [31 Maret 2024].
37. Gayatri D, Halley E. Mengenal Analisis Ketahanan (Survival Analysis). *J Keperawatan Indones* [Online] 2005;9(1):36–40. Dari : <https://media.neliti.com/media/publications/107740-ID-mengenal-analisis-ketahanan-survival-ana.pdf> [31 Maret 2024].
38. Clark TG, Bradburn MJ, Love SB, Altman DG. Survival Analysis Part I: Basic concepts and first analyses. *Br J Cancer* [Online] 2003;89(2):232–8. Dari : <https://pubmed.ncbi.nlm.nih.gov/12865907/> [31 Maret 2024].
39. Faisal AR, Bustan MN, Annas S. Analisis Survival Dengan Pemodelan Regresi Cox Proportional Hazard Menggunakan Pendekatan Bayesian. *J Stat Its Appl Teach Res* [Online] 2020;2(2):62. Dari : <https://ojs.unm.ac.id/jvariansi/article/download/14629/8749> [31 Maret 2024].
40. Dahlan MS. Analisis Survival : Dasar-Dasa Teori & Aplikasi dengan Program SPSS. Jakarta Timur: PT. Epidemiologi Indonesia; 2021.
41. Kleinbaum DG, Mitchel Klein. *Survival Analysis A Self-Learning Text*. 2nd.ed. New York: Springer; 2005.
42. Carr BI, Guerra V. Serum Inflammation Parameters and Survival in

- Hepatocellular Carcinoma Patients: Importance of Albumin and Gamma-Glutamyltranspeptidase. *Oncol* [Online] 2023;101(5):313–20. Dari : <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238618/> [2 Juli 2024].
43. Mu XM, Wang W, Jiang YY, Feng J. Patterns of comorbidity in hepatocellular carcinoma: A network perspective. *Int J Environ Res Public Health* [Online] 2020;17(9). Dari : <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246663/> [10 Mei 2024].
 44. Akkiz H, Carr BI, Bag HG, Karaoğullarından Ü, Yalçın K, Ekin N, et al. Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma. *Int J Clin Pract* [Online] 2021;75(2). Dari : <https://pubmed.ncbi.nlm.nih.gov/32583494/> [2 Juli 2024].
 45. Ali M, Parkash O. Serum Albumin Levels Relation to Tumor Aggressiveness in Patients with Hepatocellular Carcinoma from a Tertiary Care Hospital in Pakistan. *Middle East J Dig Dis* [Online] 2023;15(3):203–6. Dari : <https://pubmed.ncbi.nlm.nih.gov/38023469/> [2 Juli 2024].
 46. Lu CY, Hsiao CY, Peng PJ, Huang SC, Chuang MR, Su HJ, et al. DNA Methylation Biomarkers as Prediction Tools for Therapeutic Response and Prognosis in Intermediate-Stage Hepatocellular Carcinoma. *Cancers (Basel)* [Online] 2023;15(18). Dari : <https://pubmed.ncbi.nlm.nih.gov/37760434/> [2 Juli 2024].
 47. Sempokuya T, Forlemu A, Azawi M, Silangcruz K, Khoury N, Ma J, et al. Survival characteristics of fibrolamellar hepatocellular carcinoma: A Surveillance, Epidemiology, and End Results database study. *World J Clin Oncol* [Online] 2022;13(5):352–65. Dari : <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153071/> [3 Juli 2024].
 48. Liou WL, Tan TJY, Chen K, Goh GBB, Chang JPE, Tan CK. Gender survival differences in hepatocellular carcinoma: Is it all due to adherence to surveillance? A study of 1716 patients over three decades. *JGH Open* [Online] 2023;7(5):377–86. Dari : <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230112/> [3 Juli 2024].
 49. Ekinci O, Baran B, Ormeci AC, Soyer OM, Gokturk S, Evirgen S, et al. Current state and clinical outcome in Turkish patients with hepatocellular carcinoma. *World J Hepatol* [Online] 2018;10(1):51–61. Dari : <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787684/> [3 Juli 2024].
 50. Lee RM, Gamboa AC, Turgeon MK, Yopp A. Dissecting disease, race, ethnicity, and socioeconomic factors for hepatocellular carcinoma: An analysis from the United States Safety Net Collaborative. *Surg Oncol* [Online] 2020;35:120–5. Dari : <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982991/> [10 Juli 2024].